Search company, investor...
Collplant company logo


Founded Year




Date of IPO


Market Cap


Stock Price


About Collplant

Collplant offers CollPlant human collagen from transgenic plants with 3D printing technology.

Headquarters Location

P.O. Box 408 Kiryat Shmona


Missing: Collplant's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Collplant's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Collplant

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Collplant is included in 1 Expert Collection, including Medical Devices.


Medical Devices

242 items

Medical Device New Products & Services Tech MM (August 2021)

Collplant Patents

Collplant has filed 1 patent.

The 3 most popular patent topics include:

  • Collagens
  • Transcription factors
  • 3D computer graphics
patents chart

Application Date

Grant Date


Related Topics




Biomaterials, Polymers, Woven fabrics, Cell biology, Polymer chemistry


Application Date


Grant Date



Related Topics

Biomaterials, Polymers, Woven fabrics, Cell biology, Polymer chemistry



Latest Collplant News

Worldwide 3D Bioprinting Industry to 2027 - Players Include Aspect Biosystems, BIOLIFE4D, Brinter, Cellbricks and CollPlant -

Nov 18, 2022

November 18, 2022 09:35 AM Eastern Standard Time The global 3D Bioprinting market is expected to grow at a CAGR of 18.45% during 2022-2027. The 3D Bioprinting is a technique that allows the production of biocompatible materials and complex 3D functional living tissues. It has enabled numerous researchers and manufacturers to mimic the natural tissue microenvironment into an in-house printed 3D tissue model. It has an immense impact in the field of medicine and healthcare. The 3D bioprinting market focuses on developing application-specific bio-inks and new biomaterials, which are crucial in advancing Bio-printing tissues and organs for clinical use. Bioprinters and bio-printed tissues have gained significant interest in medicine and pharmaceutics. Besides, bioprinting technology has a broad utility in various application areas such as tissue engineering and regenerative medicine (RM), transplantation, cancer research and drug screening, and high-throughput assays. Bioprinting technology has the most recognized application in tissue engineering. Bioprinters are used to manufacture scaffolds and fabricate anatomically correct patient-specific constructs. In vitro bio-printed tissues such as skin, nerve and bone have been implanted on animals to evaluate their functionality, neovascularization, and engraftment with the host. Bioprinting's future application is expected to be mostly in organ transplantation and drug & toxicity screening. 4D bioprinting can overcome many limitations of 3D printing; hence, it has become a new field in RM and tissue engineering markets. When compared to 3D printing, 4D printing offers various advantages such as fast growth of smart and multi-materials, more flexible and deformable structures, and can add more potential applications to both 4D and 3D printing. The emergence of 4D bio-printing is gaining momentum in disease management and healthcare innovation. Technological Advancements One of the biggest trends in technological innovations is the development of magnetic bioprinters, Organ. But, a magnetic bioprinter was developed by a Russian company, 3D Bioprinting Solutions. Furthermore, the Japanese company Cyfuse Biomedical developed a platform that allows the creation of scaffold-free tissues using the Kenzan Bio-printing method to manipulate spheroids. Conversely, some companies, such as Germany-based Cellbricks, prefer to produce complex 3D printed cell culture structures with a proprietary non-commercial stereolithography-based Bio-printing platform. The enhancement in printing resolution, speed, and cost reduction are common challenges to be faced in the coming future. Germany-based Cellbricks prefer to produce complex 3D-printed cell culture structures with a proprietary non-commercial stereolithography-based Bio-printing platform. Furthermore, some enterprises try to propose bioprinters with more degrees of freedom to increase system flexibility and the range of printable features, like the American company Advanced Solutions, which has patented a six-axis robotic extrusion-based bioprinter arm, BioAssembleBot 400, which can load up to ten independent biomaterials during a single print run. Poietis, a France based Bio-printing company, focuses on laser-assisted Bio-printing combined with extrusion-based and inkjet-based technologies supported via a proprietary privacy impact assessment (PIA) software to reconstitute the 3D picture of a complete tissue with all layers. Aspect Biosystems, a Canada-based Bio-printing company, attempts to achieve improved accuracy in developing microfluidic platforms equipped with an on-printhead crosslinking system that can print bioinks with a coaxial shell. Key Questions Answered: 2. What is the growth rate of the bio-printing market? 3. What are the growth factors in the bio-printing market? 4. Who are the key players in the bio-printing market? 5. What are the latest trends in the bio-printing market? Market Segmentation

Collplant Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Collplant Rank

Collplant Frequently Asked Questions (FAQ)

  • When was Collplant founded?

    Collplant was founded in 2004.

  • What is Collplant's latest funding round?

    Collplant's latest funding round is IPO.

  • Who are the investors of Collplant?

    Investors of Collplant include Docor International Management, Meytav Technological Incubator, Modgal Industries and Pontifax.

  • Who are Collplant's competitors?

    Competitors of Collplant include Stratasys, Onkos Surgical, restor3d, Kumovis, Neo, Centinel Spine, Vertos Medical, Markforged, Formlabs, Nexa3D and 22 more.

Compare Collplant to Competitors

Carbon Logo

Carbon is a 3D printing company that works at the intersection of hardware, software, and molecular science. Its SpeedCell is a system of connected manufacturing unit operations that enables repeatable production of end-use parts with industrial-grade materials. It caters mainly to the automotive, consumer, industrial life sciences, and dental industries. The company was founded in 2013 and is based in Redwood City, California.


Paragon28 creates new and improved solutions to the challenges faced by foot and ankle specialists.

Formlabs Logo

Formlabs designs and manufactures 3D printing systems for engineers, designers, and artists.

Cyfuse Biomedical

Cyfuse Biomedical is focused on the development, manufacturing, and sales of regenerative medicine-related products. The company aims to contribute to the medical fields of regenerative medicine and drug discovery by generating steric tissues and organs. The company has developed Regenova, a 3D bioprinter.

Vertos Medical

Vertos Medical is a medical device company committed to developing minimally invasive treatments for lumbar spinal stenosis (LSS). Its proprietary technologies include mild®, which offers a safe, outpatient, minimally invasive, fluoroscopically guided therapeutic LSS treatment that requires no general anesthesia, no implants, and no stitches. LSS is primarily a degenerative, age-related narrowing of the lower spinal canal that causes symptoms of pain and numbness in the lower back, legs, or buttocks. mild® treats this condition by restoring space in the spinal canal using specialized mild® devices to remove hypertrophic ligamentum flavum through a 5.1 mm treatment portal. Clinical trials show that mild® can help LSS patients stand longer and walk farther with less pain1, and no major device-related complications have been reported.2

Onkos Surgical Logo
Onkos Surgical

Onkos Surgical is a specialty medtech company dedicated to advancing surgical oncology solutions. Onkos Surgical is developing products for both hard and soft-tissue applications. The company was founded in 2015 and is based in Parsippany, New Jersey.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.